A new allelic discrimination assay using locked nucleic acid-modified nucleotides (LNA) probes for detection of JAK2 V617F mutation [8]

Leukemia and Lymphoma

Volumn 48, Issue 3, 2007, Pages 636-639

  Marková, Jana ^a   Průková, Dana ^b   Volková, Zuzana ^a   Schwarz, Jiří ^a  

^a INSTITUTE OF MATHEMATICS   (Czech Republic)

^b INSTITUTE OF MOLECULAR GENETICS   (Czech Republic)

Author keywords

[No Author keywords available]

Indexed keywords

6 CARBOXYFLUORESCEIN; COMPLEMENTARY DNA; JANUS KINASE 2; LOCKED NUCLEIC ACID;

AMINO ACID SUBSTITUTION; CONTROLLED STUDY; GENETIC ANALYSIS; GENETIC ASSOCIATION; GRANULOCYTE; HUMAN; HUMAN CELL; INTERMETHOD COMPARISON; LETTER; MAJOR CLINICAL STUDY; MUTATIONAL ANALYSIS; MYELOID METAPLASIA; MYELOPROLIFERATIVE DISORDER; NUCLEIC ACID PROBE; PHILADELPHIA CHROMOSOME NEGATIVE CELL; POLYCYTHEMIA; POLYCYTHEMIA VERA; PRIORITY JOURNAL; REPRODUCIBILITY; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SENSITIVITY AND SPECIFICITY; THROMBOCYTHEMIA; THROMBOCYTOSIS;

BIOLOGICAL ASSAY; FLUORESCENCE; HUMANS; JANUS KINASE 2; LEUKEMIA, MYELOID, PHILADELPHIA-NEGATIVE; MUTATION; MYELOPROLIFERATIVE DISORDERS; OLIGONUCLEOTIDES, ANTISENSE; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION;

EID: 33947707255     PISSN: 10428194     EISSN: 10292403     Source Type: Journal    
DOI: 10.1080/10428190601137328     Document Type: Letter

References (13)

1. Nelson, M. E. and Steensma, D. P. (2006) JAK2 V617F in myeloid disorders: What do we know now, and where are we headed?. Leuk Lymphoma, 47, pp. 177-194.
2. Campbell, P. J., Scott, L. M., Buck, G., Wheatley, K., East, C. L. and Marsden, J. T. (2005) Definition of subtypes of essential thrombocythaemia and relation to polycythaemia vera based on JAK2 V617F mutation status: A prospective study. Lancet, 366, pp. 1945-1953.
3. Greiner, T. C. (2006) Diagnostic assays for the JAK2 V617F mutation in chronic myeloproliferative disorders. Am J Clin Pathol, 125, pp. 651-653.
4. Livak, K. J. (1999) Allelic discrimination using fluorogenic probes and the 5' nuclease assay. Genet Anal, 14, pp. 143-149.
5. Shi, M. M. (2001) Enabling large-scale pharmacogenetic studies by high-throughput mutation detection and genotyping technologies. Clin Chem, 47, pp. 164-172.
6. Latorra, D., Campbell, K., Wolter, A. and Hurley, J. M. (2003) Enhanced allele-specific PCR discrimination in SNP genotyping using 3' locked nucleic acid (LNA) primers. Hum Mutat, 22, pp. 79-85.
7. Baxter, E. J., Scott, L. M., Campbell, P. J., East, C., Fourouclas, N. and Swanton, S. (2005) Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders. Lancet, 365, pp. 1054-1061.
8. Zhao, R., Xing, S. and Krantz, S. B. (2005) Identification of an acquired JAK2 mutation in polycythemia vera. J Biol Chem, 280, pp. 22788-22792.
9. Peková, S., Marková, J., Pajer, P., Dvořák, M., Cetkovský, P. and Schwarz, J. (2005) Touch-down reverse transcriptase-PCR detection of IgVH rearrangement and Sybr-Green-based real-time RT-PCR quantitation of minimal residual disease in patients with chronic lymphocytic leukemia. Mol Diagn, 9, pp. 23-34.
10. Picard, C., Silvy, M. and Gabert, J. (2006) Overview of real-time RT-PCR strategies for quantification of gene rearrangements in the myeloid malignancies. Methods Mol Med, 125, pp. 27-68.
11. Wolanskyj, A. P., Lasho, T. L., Schwager, S. M., McClure, R. F., Wadleigh, M. and Lee, S. J. (2005) JAK2 mutation in essential thrombocythaemia: Clinical associations and long-term prognostic relevance. Br J Haematol, 131, pp. 208-213.
12. Jones, A. V., Kreil, S., Zoi, K., Waghorn, K., Curtis, C. and Zhang, L. (2005) Widespread occurrence of the JAK2 V617F mutation in chronic myeloproliferative disorders. Blood, 106, pp. 2162-2168.
13. Scott, L. M., Scott, M. A., Campbell, P. J. and Green, A. R. (2006) Progenitors homozygous for the V617F mutation occur in most patients with polycythemia vera, but not essential thrombocythemia. Blood, 108, pp. 2435-2437.